ReNeuron Group Overview

  • Founded
  • 1997
Founded
  • Status
  • Public
  • Employees
  • 38
Employees
  • Stock Symbol
  • RENE
Stock Symbol
  • Investments
  • 1
  • Share Price
  • $1.27
  • (As of Thursday Closing)

ReNeuron Group General Information

Description

ReNeuron Group PLC is engaged in the field of biotechnology. Its core activities include the research and clinical development of cell-based therapeutics. The company product pipeline includes human retinal progenitor cell line (hRPC) and CTX neural cell line. It derives revenue from UK and US. The company is mainly focusing on the treatment of stroke disability, inherited retinal diseases, and cancer.

Contact Information

Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Pharmaceuticals
Stock Exchange
LON
Primary Office
  • Pencoed Business Park
  • Pencoed
  • Bridgend CF35 5HY
  • Wales, United Kingdom
+44 020 0000 0000

ReNeuron Group Timeline

2018201920202021
Financing RoundCaptured Employee CountEstimated Employee Growth
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

ReNeuron Group Stock Performance

(As of Thursday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$1.27 $1.31 $0.94 - $2.14 $74.6M 56.9M 86.1K -$0.38

ReNeuron Group Financials Summary

In Thousands,
USD
TTM 31-Mar-2021 FY 2021 31-Mar-2021 FY 2020 31-Mar-2020 FY 2019 31-Mar-2019
EV 81,063 81,063 14,004 2,377
Revenue 335 335 7,705 64
EBITDA (16,989) (16,989) (17,393) (22,445)
Net Income (14,808) (14,808) (14,498) (18,830)
Total Assets 34,845 34,845 25,205 41,099
Total Debt 988 988 1,080 1,311
Public Fundamental Data provided by Morningstar, Inc. disclaimer

ReNeuron Group Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore ReNeuron Group‘s full profile, request access.

Request a free trial

ReNeuron Group Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
ReNeuron Group PLC is engaged in the field of biotechnology. Its core activities include the research and clinical devel
Drug Discovery
Bridgend, United Kingdom
38 As of 2021
00000
00000000000 00000

0000000

in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occ
0000000000000
London, Canada
00 As of 0000
000.00
00000000 000.00

0000000

tetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad
0000 000000000
San Diego, CA
000 As of 0000
00000
00000000000 00000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

ReNeuron Group Competitors (37)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Sernova Corporation London, Canada 00 000.00 00000000 000.00
0000000 Venture Capital-Backed San Diego, CA 000 00000 00000000000 00000
0000000 Formerly VC-backed Leuven, Belgium 00 00000 000000&0 00000
000000000 00000000 Formerly Accelerator/Incubator backed New York, NY 00 000.00 000000 - 000 000.00
000000 Formerly VC-backed Ghent, Belgium 000 00000 000000&0 00000
You’re viewing 5 of 37 competitors. Get the full list »

ReNeuron Group Executive Team (15)

Name Title Board Seat Contact Info
Olav Hellebo Chief Executive Officer & Board Member
Stefano Pluchino Ph.D Chief Scientific Officer
Randolph Corteling Ph.D Head of Research
Shaun Stapleton Vice President Regulatory Affairs and Pharmacovigilence
Richard Beckman MD Chief Medical Officer
You’re viewing 5 of 15 executive team members. Get the full list »

ReNeuron Group Board Members (10)

Name Representing Role Since
Christopher Evans Excalibur Group Holdings Board Member 000 0000
Michael Owen Ph.D Self Board Member 000 0000
Olav Hellebo ReNeuron Group Chief Executive Officer & Board Member 000 0000
You’re viewing 3 of 10 board members. Get the full list »

ReNeuron Group Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

ReNeuron Group Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore ReNeuron Group‘s full profile, request access.

Request a free trial

ReNeuron Group Acquisitions (1)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
000000 27-Jul-2007 000000000000000000 000 Drug Delivery 0000000 0000
To view ReNeuron Group’s complete acquisitions history, request access »